Title : Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer.

Pub. Date : 2019 Nov 26

PMID : 31772161






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRbeta-IL-6 axis in MUC1-positive cervical cancer. erlotinib mucin 1, cell surface associated Homo sapiens
2 Collectively, our work has demonstrated that the MUC1-EGFR-CREB/GRbeta axis stimulates IL-6 expression to induce CSCs enrichment and importantly, this effect can be abrogated by erlotinib, uncovering a novel strategy to treat paclitaxel-resistant cervical cancer. erlotinib mucin 1, cell surface associated Homo sapiens